Urologix Inc  

(Public, OTCMKTS:ULGX)   Watch this stock  
Find more results for ULGX
+0.00060 (25.00%)
Delayed:   11:34AM EST
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.00 - 0.00
52 week 0.00 - 0.16
Open 0.00
Vol / Avg. 137,000.00/78,038.00
Mkt cap 58,178.00
P/E     -
Div/yield     -
EPS -0.22
Shares 21.82M
Beta 1.31
Inst. own 24%

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -12.48% -53.45%
Operating margin -5.47% -48.68%
EBITD margin - -23.23%
Return on average assets -27.07% -83.63%
Return on average equity - -
Employees 61 -
CDP Score - -


14405 21st Ave N
MINNEAPOLIS, MN 55447-4685
United States - Map
+1-612-4751400 (Phone)
+1-763-4048118 (Fax)

Website links


Urologix, Inc., the United States based company, develops, manufactures, markets and distributes non-surgical, office-based therapies for the treatment of the symptoms and obstruction resulting from non-cancerous prostate enlargement also known as benign prostatic hyperplasia (BPH). Urologix’s Cooled ThermoTherapy produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva RF Therapy System delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH symptoms. Both of these therapies provide safe, effective and lasting relief of the symptoms and obstruction due to BPH.

Officers and directors

Gregory J. Fluet Chief Executive Officer, Director
Age: 45
Scott M Madson Chief Financial Officer
Age: 51
Lisa A. Ackermann Executive Vice President - Sales and Marketing
Age: 42
Mitchell Dann Independent Non-Executive Chairman of the Board, Lead Director
Age: 54
Christopher R. Barys Independent Director
Age: 48
Sidney W. Emery Jr. Independent Director
Age: 68
Patrick D. Spangler Independent Director
Age: 59